Know Cancer

forgot password

The Utility of Positron Emission Tomography (PET) in Staging of Patients With Potentially Operable Non-Small Cell Lung Carcinoma

18 Years
Not Enrolling
Lung Cancer

Thank you

Trial Information

The Utility of Positron Emission Tomography (PET) in Staging of Patients With Potentially Operable Non-Small Cell Lung Carcinoma


- Determine the efficacy of fludeoxyglucose F 18 positron emission tomography (FDG-PET)
in detecting lesions that would preclude pulmonary resection in patients with non-small
cell lung cancer.

OUTLINE: This is a multicenter study.

Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron
emission tomography (PET) imaging. Confirmatory studies, such as biopsy, fine needle
aspiration, or other imaging studies are then conducted to confirm the PET findings.

Patients with no mediastinal nodal or distant metastases identified by FDG-PET scan may
undergo thoracotomy and pulmonary resection within 1 month of evaluation.

Patients are followed at 5-6 months after surgery.

PROJECTED ACCRUAL: A total of 120-235 patients will be accrued for this study.

Inclusion Criteria


- Histologically or cytologically proven clinical stage I, II, or IIIA single lesion
bronchogenic non-small cell lung cancer (NSCLC)

- Adenocarcinoma

- Nonlobar/nondiffuse bronchoalveolar cell carcinoma

- Large cell carcinoma

- Squamous cell carcinoma

- Mediastinal node histology diagnosed by transbronchial biopsy

- Biopsy not required if separate ipsilateral lung lesion clearly evident on

- Suspected primary bronchogenic carcinoma allowed without histologic or cytologic
proof (e.g., heavy smoker with new peripheral mass with typical appearance of lung
cancer on x-ray) if:

- Tumor clinically resectable

- Exploratory thoracotomy planned

- Newly diagnosed, untreated disease amenable to curative surgery

- No prior positron emission tomography (PET) scan for NSCLC



- 18 and over

Performance status:

- Not specified

Life expectancy:

- Not specified


- Not specified


- Not specified


- Not specified


- Able to tolerate PET

- Not claustrophobic

- Able to lie supine for 1.5 hours

- Medically fit for surgical staging procedures or clinical resection

- Not pregnant or nursing

- Negative pregnancy test

- No uncontrolled diabetes mellitus as evidenced by fasting blood glucose greater than
200 mg/dL

- No prior malignancy within the past 5 years except completely resected cervical
cancer or nonmelanoma skin cancer or cancer that has been treated with potentially
curative therapy and is deemed to be at low risk for recurrence


Biologic therapy

- Not specified


- Not specified

Endocrine therapy

- Not specified


- Not specified


- See Disease Characteristics

Type of Study:


Study Design:

Primary Purpose: Diagnostic

Principal Investigator

Carolyn E. Reed, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Medical University of South Carolina


United States: Federal Government

Study ID:




Start Date:

September 1999

Completion Date:

Related Keywords:

  • Lung Cancer
  • stage I non-small cell lung cancer
  • stage II non-small cell lung cancer
  • squamous cell lung cancer
  • large cell lung cancer
  • stage IIIA non-small cell lung cancer
  • adenocarcinoma of the lung
  • bronchoalveolar cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Memorial Sloan-Kettering Cancer Center New York, New York  10021
Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781
University of Chicago Cancer Research Center Chicago, Illinois  60637
Indiana University Cancer Center Indianapolis, Indiana  46202-5265
Duke Comprehensive Cancer Center Durham, North Carolina  27710
Medical University of South Carolina Charleston, South Carolina  29425-0721
Mount Sinai School of Medicine New York, New York  10029
UCSF Cancer Center and Cancer Research Institute San Francisco, California  94115-0128
Barnes-Jewish Hospital Saint Louis, Missouri  63110
Massachusetts General Hospital Cancer Center Boston, Massachusetts  02114
Massey Cancer Center Richmond, Virginia  23298-0037
Holden Comprehensive Cancer Center Iowa City, Iowa  52242-1009
Allegheny General Hospital Pittsburgh, Pennsylvania  15212-4772
William Beaumont Hospital Royal Oak, Michigan  48073
Marlene and Stewart Greenebaum Cancer Center, University of Maryland Baltimore, Maryland  21201-1595
Lutheran General Hospital Park Ridge, Illinois  60068
Latter Day Saints Hospital Salt Lake City, Utah  84143
Western Pennsylvania Cancer Institute Pittsburgh, Pennsylvania  15224
Morton Plant Mease Health Care Clearwater, Florida  33756
Jameson Memorial Hospital New Castle, Pennsylvania  16105
Lakeland Regional Medical Center Lakeland, Florida  33804
Veterans Affairs Medical Center - Iowa City Iowa City, Iowa  52246-2208
Westmoreland Hospital Greensburg, Pennsylvania  15601-2282